Printer Friendly
The Free Library
19,573,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

ANALYST INTERVIEW: OUTLOOK FOR BIOTECHNOLOGY: FARIBA GHODSIAN - ROTH CAPITAL PARTNERS.


(NAY903) OUTLOOK FOR BIOTECHNOLOGY: FARIBA GHODSIAN - ROTH CAPITAL PARTNERS Roth Capital Partners, LLC, is a full service Investment Banking firm, specializing in the small and micro cap markets. Roth’s focus, according to its official website, "has been, is, and will continue to be providing the full spectrum of investment banking services, . Reviews the performance of the industry, and examines recent changes that have impacted companies in that sector. Topics discussed include competition, mergers and acquisitions, and the development of customer demand; and a number of companies are identified that are considered well positioned to succeed in the current market. Sector: Biotechnology. Published date 2/18/02. Tickers featured: ALLP ALLP Aldo Leopold Leadership Program , AMGN, AVGN AVGN Angry Video Game Nerd , BAX, CORR CORR

Used on the consolidated tape to indicate a correction in a reported transaction : CORR.LAST.GY 50 WAS 51.
, IDBE, IMCL/BMY, IMNX, ISIP, KERX, LLY, MEDI, MEDX, MLNM, NABI, NWBT, SHR. Complete text approximately 3000 words. Document # NAY903.

ANALYST INTERVIEWS, The Wall Street Transcript, 67 Wall Street, NY 10005. Voice (212) 952 7433. Fax: (212) 668-9842. E-mail: transcript@twst.com.

***
COPYRIGHT 2002 Wall Street Transcript Corporation
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Comment:ANALYST INTERVIEW: OUTLOOK FOR BIOTECHNOLOGY: FARIBA GHODSIAN - ROTH CAPITAL PARTNERS.
Publication:Wall Street Transcript Digest
Article Type:Brief Article
Geographic Code:1USA
Date:Feb 19, 2002
Words:113
Previous Article:CEO INTERVIEW: PAUL RYAN - ACACIA RESEARCH CORPORATION (ACRI).
Next Article:ANALYST INTERVIEW: WIRELESS TECHNOLOGY & SOFTWARE: DANIEL CAMPBELL II - ROTH CAPITAL PARTNERS.
Topics:



Related Articles
ANALYST INTERVIEW: OUTLOOK FOR BIOTECHNOLOGY STOCKS: FARIBA GHODSIAN - ROTH CAPITAL PARTNERS.
AMGEN WINS APPROVAL FOR NEW DRUG NEULASTA ADDS VALUE TO FIRM.
DRUG MAKER BEATS SEERS TREATMENTS LIFT AMGEN.
BIOTECH DRUG OKS COULD STALL FDA SHIFT MAY MEAN LONGER APPROVAL WAIT.
ANALYST INTERVIEW: FUNDING BIOTECH COMPANIES: FARIBA GHODSIAN - ROTH CAPITAL PARTNERS.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles